Phase 3 Childhood-Onset Growth Hormone Deficiency Trial Continues Enrollment
jarmoluk / Pixabay

Phase 3 Childhood-Onset Growth Hormone Deficiency Trial Continues Enrollment

Aeterna Zentaris’s ongoing DETECT trial is evaluating the drug macimorelin (tradename Macrilen™) for childhood-onset growth hormone deficiency (CGHD). As recently announced in an article published by GlobeNewsWire, the study (AEZS-130-PO2),…

Continue Reading Phase 3 Childhood-Onset Growth Hormone Deficiency Trial Continues Enrollment
Ways to Support Those with Pediatric Growth Hormone Deficiency
source: pixabay.com

Ways to Support Those with Pediatric Growth Hormone Deficiency

Growth hormone deficiency (GHD) influences patients both physically and mentally. The condition means patients' bodies don't produce enough growth hormone. As a result, they don't develop the same way as…

Continue Reading Ways to Support Those with Pediatric Growth Hormone Deficiency
An Experimental Treatment for Growth Hormone Deficiency Performs Well in Phase 3 Trial
Free-Photos / Pixabay

An Experimental Treatment for Growth Hormone Deficiency Performs Well in Phase 3 Trial

According to a story from globenewswire.com, the experimental drug somatrogon, which is being co-developed by Pfizer, Inc. and OPKO Health, Inc., was able to achieve its primary endpoint in a…

Continue Reading An Experimental Treatment for Growth Hormone Deficiency Performs Well in Phase 3 Trial